In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET

被引：90

作者：

Kikuchi, Akio ^{[1
]}

Okamura, Nobuyuki ^{[2
]}

Hasegawa, Takafumi ^{[1
]}

Harada, Ryuichi ^{[2
]}

Watanuki, Shoichi ^{[4
]}

Funaki, Yoshihito ^{[5
]}

Hiraoka, Kotaro ^{[4
]}

Baba, Toru ^{[1
]}

Sugeno, Naoto ^{[1
]}

Oshima, Ryuji ^{[1
]}

Yoshida, Shun ^{[1
]}

Kobayashi, Junpei ^{[1
]}

Ezura, Michinori ^{[1
]}

Kobayashi, Michiko ^{[8
]}

Tano, Ohito ^{[9
]}

Mugikura, Shunji ^{[3
]}

Iwata, Ren ^{[5
]}

Ishiki, Aiko ^{[6
]}

Furukawa, Katsutoshi ^{[6
]}

Arai, Hiroyuki ^{[6
]}

Furumoto, Shozo ^{[5
]}

Tashiro, Manabu ^{[4
]}

Yanai, Kazuhiko ^{[2
]}

Kudo, Yukitsuka ^{[7
]}

Takeda, Atsushi ^{[10
]}

Aoki, Masashi ^{[1
]}

机构：

[1] Tohoku Univ, Grad Sch Med, Dept Neurol, Sendai, Miyagi, Japan

[2] Tohoku Univ, Grad Sch Med, Dept Pharmacol, Sendai, Miyagi, Japan

[3] Tohoku Univ, Grad Sch Med, Dept Diagnost Radiol, Sendai, Miyagi, Japan

[4] Tohoku Univ, Ctr Cyclotron & Radioisotope, Div Cyclotron Nucl Med, Sendai, Miyagi, Japan

[5] Tohoku Univ, Ctr Cyclotron & Radioisotope, Div Radiopharmaceut Chem, Sendai, Miyagi, Japan

[6] Tohoku Univ, Inst Dev Aging & Canc, Dept Geriatr & Resp Med, Sendai, Miyagi, Japan

[7] Tohoku Univ, Inst Dev Aging & Canc, Div Neuroimaging, Sendai, Miyagi, Japan

[8] Tohoku Pharmaceut Univ Hosp, Dept Neurol, Sendai, Miyagi, Japan

[9] Sendai Med Ctr, Dept Neurol, Sendai, Miyagi, Japan

[10] Natl Hosp Org, Sendai Nishitaga Hosp, Dept Neurol, Sendai, Miyagi, Japan

来源：

NEUROLOGY | 2016年 / 87卷 / 22期

关键词：

PROGRESSIVE SUPRANUCLEAR PALSY; BETA-AMYLOID BURDEN; ALZHEIMERS-DISEASE; NEUROFIBRILLARY PATHOLOGY; DEGENERATION; DEMENTIA; TAUOPATHIES; DIAGNOSIS;

D O I：

10.1212/WNL.0000000000003375

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To determine whether F-18-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS). Methods: We evaluated the in vitro binding of H-3-THK5351 in postmortem brain tissues from a patient with corticobasal degeneration (CBD). In clinical PET studies, F-18-THK5351 retention in 5 patients with CBS was compared to that in 8 age-matched normal controls and 8 patients with Alzheimer disease (AD). Results: H-3-THK5351 was able to bind to tau deposits in the postmortem brain with CBD. In clinical PET studies, the 5 patients with CBS showed significantly higher F-18-THK5351 retention in the frontal, parietal, and globus pallidus than the 8 age-matched normal controls and patients with AD. Higher F-18-THK5351 retention was observed contralaterally to the side associated with greater cortical dysfunction and parkinsonism. Conclusions: F-18-THK5351 PET demonstrated high tracer signal in sites susceptible to tau deposition in patients with CBS. F-18-THK5351 should be considered as a promising candidate radio-tracer for the in vivo imaging of tau deposits in CBS.

引用

页码：2309 / 2316

页数：8

共 50 条

[41] Investigation of the selectivity of Tau PET radioligand THK5351 in vitro and in vivo
Guo, Q.
Otterstaetter, B.
Benninghoff, S.
Reuter, D.
Wang, J.
Skaddan, M.
Tovcimak, A.
Schroeder, C.
Krishnan, G.
Wilcox, K.
Comley, R.
Makidon, P.
Voorbach, M.
Haupt, A.
Mugnaini, M.
Martarello, L.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 : 84 - 85
[42] Characterization of the radiosynthesis and purification of [18F]THK-5351, a PET ligand for neurofibrillary tau
Betthauser, Tobey J.
Ellison, Paul A.
Murali, Dhanabalan
Lao, Patrick J.
Barnhart, Todd E.
Furtunoto, Shozo
Okamura, Nobuyuki
Johnson, Sterling C.
Engle, Jonathan W.
Nickles, Robert J.
Christian, Bradley T.
APPLIED RADIATION AND ISOTOPES, 2017, 130 : 230 - 237
[43] Distribution Pattern of the Monoamine Oxidase B Ligand, 18F-THK5351, in the Healthy Brain
Ishibashi, Kenji
Miura, Yoshiharu
Tago, Tetsuro
Toyohara, Jun
Higashihara, Mana
Iwata, Atsushi
Ishii, Kenji
CLINICAL NUCLEAR MEDICINE, 2022, 47 (07) : E489 - E495
[44] Increased Uptake of 18F-THK5351 in Glioblastoma But Not in Primary Central Nervous System Lymphoma
Mitamura, Katsuya
Norikane, Takashi
Yamamoto, Yuka
Miyake, Keisuke
Nishiyama, Yoshihiro
CLINICAL NUCLEAR MEDICINE, 2021, 46 (09) : 772 - 773
[45] 18F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
Jung-Lung Hsu
Shih-Hsin Chen
Ing-Tsung Hsiao
Chin-Song Lu
Tzu-Chen Yen
Nobuyuki Okamura
Kun-Ju Lin
Yi-Hsin Weng
Scientific Reports, 10
[46] Potential Use of 18F-THK5351 PET to Identify Wallerian Degeneration of the Pyramidal Tract Caused by Cerebral Infarction
Ishibashi, Kenji
Kameyama, Masashi
Tago, Tetsuro
Toyohara, Jun
Ishii, Kenji
CLINICAL NUCLEAR MEDICINE, 2017, 42 (12) : E523 - E524
[47] Increased Uptake of 18F-THK5351 in Isocitrate Dehydrogenase-Wildtype Glioblastoma But Not in Meningioma
Mitamura, Katsuya
Norikane, Takashi
Yamamoto, Yuka
Miyake, Keisuke
Nishiyama, Yoshihiro
CLINICAL NUCLEAR MEDICINE, 2024, 49 (10) : 962 - 963
[48] Clinical Application of 18F-THK5351 PET to Identify Inflammatory Lesions Through Imaging Astrogliosis in a Case of Cytomegalovirus Ventriculoencephalitis
Hatano, Keiko
Ishibashi, Kenji
Yamada, Kazuki
Ishii, Kenji
Iwata, Atsushi
CLINICAL NUCLEAR MEDICINE, 2023, 48 (10) : E489 - E490
[49] 18F-THK5351 PET Is Superior to Conventional MRI in Identifying Inflammatory Lesions by Imaging Astrogliosis in 2 Cases of Neurosyphilis
Kotani, Risa
Hatano, Keiko
Ishibashi, Kenji
Iwata, Atsushi
CLINICAL NUCLEAR MEDICINE, 2024, 49 (12) : E677 - E679
[50] Combination of 18F-FDG PET and 18F-THK5351 PET for distinguishing glioblastoma and metastatic brain tumor and primary central nervous system lymphoma
Mitamura, Katsuya
Norikane, Takashi
Yamamoto, Yuka
Nishiyama, Yoshihiro
JOURNAL OF NUCLEAR MEDICINE, 2024, 65

← 1 2 3 4 5 →